復星醫藥(02196.HK):董事會宣佈議決採納復星健康股權激勵計劃
格隆匯2月13日丨復星醫藥(02196.HK)董事會宣佈於2022年2月11日議決採納復星健康股權激勵計劃,旨在激勵及留聘有利於公司附屬公司復星健康業務發展的人才(包括激勵對象),從而促進復星健康長遠發展。
根據該計劃,擬通過向合夥平台轉讓寧波礪定(以持有標的股權為單一目的持股平台)現有合夥人之合夥份額以使激勵對象透過相關合夥平台及寧波礪定間接擁有標的股權的權益。
採納該計劃後,復星健康擬向激勵對象作出首次授予,所涉及激勵權益總額約佔不超過復星健康全部股權的5.008%;餘下激勵權益(約佔復星健康全部股權約2.992%)將用於符合該計劃規定的後續授予。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.